These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Phase II trial of doxorubicin therapy for advanced islet cell carcinoma.
    Author: Moertel CG, Lavin PT, Hahn RG.
    Journal: Cancer Treat Rep; 1982 Jul; 66(7):1567-9. PubMed ID: 6284361.
    Abstract:
    Twenty evaluable patients with advanced islet cell carcinoma were treated with doxorubicin at a dosage of 60 mg/m2 every 3-4 weeks. Toxicity was clinically tolerable and characteristic of doxorubicin therapy. Although all patients had previously been treated with other chemotherapy regiments, four (20%) had objective therapeutic responses persisting for 2-301/2 months. Doxorubicin has definite therapeutic activity in islet cell carcinoma and is currently being evaluated in combination chemotherapy regimens.
    [Abstract] [Full Text] [Related] [New Search]